NEW YORK (GenomeWeb) — Epistem said this week that it has successfully completed a clinical evaluation of its Genedrive molecular diagnostics platform and completed a regulatory submission with the Drug Controller General of India for its first test for the diagnosis of tuberculosis and rifampin
NEW YORK (GenomeWeb) — Epistem said today that it has entered into a collaborative funding agreement with the Global Health Investment Fund to support commercialization of Epistem's Genedrive molecular diagnostic platform and tuberculosis assay.
NEW YORK (GenomeWeb News) — Epistem said yesterday that it has entered into cooperative agreements with the US Air Force and Johns Hopkins University's Advanced Physics Laboratory to undertake combat evaluation of Epistem's Genedrive molecular handheld pathogen-detection device.
NEW YORK (GenomeWeb News) – UK biotech firm Epistem said today that it has received €1.5 million ($2 million) from the European Commission to develop point-of-care diagnostic tests for Hepatitis C as part of a €6 million, international project called the PoC HCV consortium.
NEW YORK (GenomeWeb News) – UK firm Epistem today announced its intention to raise £4.2 million ($6.7 million) in net proceeds in preparation of the launch of its molecular diagnostics platform and a tuberculosis assay.
UK-based molecular diagnostics developer Epistem said this week that Becton Dickinson will distribute Epistem's point-of-care assay for Mycobacterium tuberculosis and rifampin resistance on a global basis excluding India and the Indian sub-continent.